Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000905148-25-001900
Filing Date
2025-05-23
Accepted
2025-05-23 16:58:19
Documents
3
Period of Report
2025-05-21

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 5620
2 blume-jensen_poa.htm EX-24.1 11977
3 masson_poa.htm EX-24.2 11979
  Complete submission text file 0000905148-25-001900.txt   31367
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Issuer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address
Blume-Jensen Peter (Reporting) CIK: 0001950499 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41551 | Film No.: 25983212

Mailing Address C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address
Masson Kristina (Reporting) CIK: 0001950501 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41551 | Film No.: 25983211